Medicare’s National Coverage Determination for Aducanumab — A One-Off or a Pragmatic Path Forward?
As it did with aducanumab, CMS could use the coverage with evidence development program to address residual uncertainty regarding benefits and harms for an increasing number of FDA-regulated products.
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2022-10, Vol.387 (17), p.1539-1541 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1541 |
|---|---|
| container_issue | 17 |
| container_start_page | 1539 |
| container_title | The New England journal of medicine |
| container_volume | 387 |
| creator | Dhruva, Sanket S. Ramachandran, Reshma Ross, Joseph S. |
| description | As it did with aducanumab, CMS could use the coverage with evidence development program to address residual uncertainty regarding benefits and harms for an increasing number of FDA-regulated products. |
| doi_str_mv | 10.1056/NEJMp2210198 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2729514492</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2729514492</sourcerecordid><originalsourceid>FETCH-LOGICAL-c325t-c56f713a692589606e4a935355665178a00449036ab219a6282dc0d4a1f1f27d3</originalsourceid><addsrcrecordid>eNpt0L1OwzAQB3ALgUQpbDyAJRgYCPg78YSq0vKh0naAObomNqRqkmInILY-BAuv1yfBUAaEuOWG-91J90fokJIzSqQ6Hw9u75aMUUJ1soU6VHIeCUHUNuoQwpJIxJrvoj3v5yQUFbqD7J3JiwycWa8-PB5DU9QVLHC_fjEOHg2-NI1xZVF9D7CtHe7lbQZVW8IMr1fvuIcnlYkm1uIwAzwNW2XAGZ5C84SHtXsFl1_sox0LC28OfnoXPQwH9_3raDS5uun3RlHGmWyiTCobUw5KM5loRZQRoLnkUiolaZwAIUJowhXMGNWgWMLyjOQCqKWWxTnvopPN3aWrn1vjm7QsfGYWC6hM3fqUxUxLGm6wQI_-0HnduvD8RhGlVSKCOt2ozNXeO2PTpStKcG8pJelX6Onv0AM_3vCy9Gll5uX_7BPzI34F</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2729069684</pqid></control><display><type>article</type><title>Medicare’s National Coverage Determination for Aducanumab — A One-Off or a Pragmatic Path Forward?</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Dhruva, Sanket S. ; Ramachandran, Reshma ; Ross, Joseph S.</creator><creatorcontrib>Dhruva, Sanket S. ; Ramachandran, Reshma ; Ross, Joseph S.</creatorcontrib><description>As it did with aducanumab, CMS could use the coverage with evidence development program to address residual uncertainty regarding benefits and harms for an increasing number of FDA-regulated products.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMp2210198</identifier><language>eng</language><publisher>Boston: Massachusetts Medical Society</publisher><subject>Aging ; Aging General ; Alzheimer Disease ; Alzheimer's disease ; and the FDA ; Beneficiaries ; Clinical outcomes ; Dementia ; Devices ; Drugs ; Enrollments ; FDA approval ; Geriatrics ; Health Policy ; Medical equipment ; Medicare ; Medicare and Medicaid ; Monoclonal antibodies ; Neurology ; Neurosurgery ; Older people ; Patients ; Prescription drugs</subject><ispartof>The New England journal of medicine, 2022-10, Vol.387 (17), p.1539-1541</ispartof><rights>Copyright © 2022 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c325t-c56f713a692589606e4a935355665178a00449036ab219a6282dc0d4a1f1f27d3</citedby><cites>FETCH-LOGICAL-c325t-c56f713a692589606e4a935355665178a00449036ab219a6282dc0d4a1f1f27d3</cites><orcidid>0000-0002-9218-3320 ; 0000-0003-0674-2032</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMp2210198$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2729069684?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids></links><search><creatorcontrib>Dhruva, Sanket S.</creatorcontrib><creatorcontrib>Ramachandran, Reshma</creatorcontrib><creatorcontrib>Ross, Joseph S.</creatorcontrib><title>Medicare’s National Coverage Determination for Aducanumab — A One-Off or a Pragmatic Path Forward?</title><title>The New England journal of medicine</title><description>As it did with aducanumab, CMS could use the coverage with evidence development program to address residual uncertainty regarding benefits and harms for an increasing number of FDA-regulated products.</description><subject>Aging</subject><subject>Aging General</subject><subject>Alzheimer Disease</subject><subject>Alzheimer's disease</subject><subject>and the FDA</subject><subject>Beneficiaries</subject><subject>Clinical outcomes</subject><subject>Dementia</subject><subject>Devices</subject><subject>Drugs</subject><subject>Enrollments</subject><subject>FDA approval</subject><subject>Geriatrics</subject><subject>Health Policy</subject><subject>Medical equipment</subject><subject>Medicare</subject><subject>Medicare and Medicaid</subject><subject>Monoclonal antibodies</subject><subject>Neurology</subject><subject>Neurosurgery</subject><subject>Older people</subject><subject>Patients</subject><subject>Prescription drugs</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0L1OwzAQB3ALgUQpbDyAJRgYCPg78YSq0vKh0naAObomNqRqkmInILY-BAuv1yfBUAaEuOWG-91J90fokJIzSqQ6Hw9u75aMUUJ1soU6VHIeCUHUNuoQwpJIxJrvoj3v5yQUFbqD7J3JiwycWa8-PB5DU9QVLHC_fjEOHg2-NI1xZVF9D7CtHe7lbQZVW8IMr1fvuIcnlYkm1uIwAzwNW2XAGZ5C84SHtXsFl1_sox0LC28OfnoXPQwH9_3raDS5uun3RlHGmWyiTCobUw5KM5loRZQRoLnkUiolaZwAIUJowhXMGNWgWMLyjOQCqKWWxTnvopPN3aWrn1vjm7QsfGYWC6hM3fqUxUxLGm6wQI_-0HnduvD8RhGlVSKCOt2ozNXeO2PTpStKcG8pJelX6Onv0AM_3vCy9Gll5uX_7BPzI34F</recordid><startdate>20221027</startdate><enddate>20221027</enddate><creator>Dhruva, Sanket S.</creator><creator>Ramachandran, Reshma</creator><creator>Ross, Joseph S.</creator><general>Massachusetts Medical Society</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9218-3320</orcidid><orcidid>https://orcid.org/0000-0003-0674-2032</orcidid></search><sort><creationdate>20221027</creationdate><title>Medicare’s National Coverage Determination for Aducanumab — A One-Off or a Pragmatic Path Forward?</title><author>Dhruva, Sanket S. ; Ramachandran, Reshma ; Ross, Joseph S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c325t-c56f713a692589606e4a935355665178a00449036ab219a6282dc0d4a1f1f27d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aging</topic><topic>Aging General</topic><topic>Alzheimer Disease</topic><topic>Alzheimer's disease</topic><topic>and the FDA</topic><topic>Beneficiaries</topic><topic>Clinical outcomes</topic><topic>Dementia</topic><topic>Devices</topic><topic>Drugs</topic><topic>Enrollments</topic><topic>FDA approval</topic><topic>Geriatrics</topic><topic>Health Policy</topic><topic>Medical equipment</topic><topic>Medicare</topic><topic>Medicare and Medicaid</topic><topic>Monoclonal antibodies</topic><topic>Neurology</topic><topic>Neurosurgery</topic><topic>Older people</topic><topic>Patients</topic><topic>Prescription drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dhruva, Sanket S.</creatorcontrib><creatorcontrib>Ramachandran, Reshma</creatorcontrib><creatorcontrib>Ross, Joseph S.</creatorcontrib><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dhruva, Sanket S.</au><au>Ramachandran, Reshma</au><au>Ross, Joseph S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medicare’s National Coverage Determination for Aducanumab — A One-Off or a Pragmatic Path Forward?</atitle><jtitle>The New England journal of medicine</jtitle><date>2022-10-27</date><risdate>2022</risdate><volume>387</volume><issue>17</issue><spage>1539</spage><epage>1541</epage><pages>1539-1541</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>As it did with aducanumab, CMS could use the coverage with evidence development program to address residual uncertainty regarding benefits and harms for an increasing number of FDA-regulated products.</abstract><cop>Boston</cop><pub>Massachusetts Medical Society</pub><doi>10.1056/NEJMp2210198</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-9218-3320</orcidid><orcidid>https://orcid.org/0000-0003-0674-2032</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2022-10, Vol.387 (17), p.1539-1541 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2729514492 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Aging Aging General Alzheimer Disease Alzheimer's disease and the FDA Beneficiaries Clinical outcomes Dementia Devices Drugs Enrollments FDA approval Geriatrics Health Policy Medical equipment Medicare Medicare and Medicaid Monoclonal antibodies Neurology Neurosurgery Older people Patients Prescription drugs |
| title | Medicare’s National Coverage Determination for Aducanumab — A One-Off or a Pragmatic Path Forward? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T06%3A11%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medicare%E2%80%99s%20National%20Coverage%20Determination%20for%20Aducanumab%20%E2%80%94%20A%20One-Off%20or%20a%20Pragmatic%20Path%20Forward?&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Dhruva,%20Sanket%20S.&rft.date=2022-10-27&rft.volume=387&rft.issue=17&rft.spage=1539&rft.epage=1541&rft.pages=1539-1541&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMp2210198&rft_dat=%3Cproquest_cross%3E2729514492%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2729069684&rft_id=info:pmid/&rfr_iscdi=true |